{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', '6.4', 'STUDY COMMITTEE', '6.4.1 Scientific advisory committee:', 'The scientific advisory committee (SAC) is composed of field experts and Sponsor-based', 'scientists with clinical and methodological expertise. This Committee, led by a Chairperson, is', 'selected by the Sponsor for advice regarding scientific issues and operational conduct of the', 'study. The SAC will also review any amendments, and provide input regarding interpretation of', 'study results.', 'Among its responsibilities, the SAC will receive study status reports from the Sponsor, and will', 'review the recommendations from the data monitoring committee (DMC) throughout the study.', 'Moreover, the SAC will be responsible for the primary publication(s) emanating from the study.', 'The Principal Investigator (PI) of the study will be selected by the Sponsor and will be the first', 'author for the primary publication(s). PIs at the 3 sites enrolling the most patients will also be', 'included as authors for the primary publication, in addition to the other SAC members.', 'Detailed activities and responsibilities of the SAC are provided in the SAC charter.', '6.4.2 Data monitoring committee', 'A DMC, operating independently from the Sponsor and Clinical Investigators, will be responsible', 'for overseeing the safety of patients and the risk/benefit ratio throughout the study.', 'This committee is composed of externally-based individuals with expertise in the disease under', 'study, biostatistics and/or clinical research. The primary responsibilities of the DMC are to ensure', 'the patients welfare as well as to evaluate and review the safety and other applicable data', 'throughout the course of the study and make appropriate recommendations to the Sponsor', 'regarding the conduct of the clinical trial. The specific responsibilities of the DMC will be', 'described in the DMC charter.', 'Property of the Sanofi Group - strictly confidential', 'Page 40', 'VV-CLIN-0254406: 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', '7', 'SELECTION OF PATIENTS', '7.1', 'INCLUSION CRITERIA', 'I 01. Patients with RRMS aged from 10 years to less than 18 years at study entry are eligible.', 'Patients must meet the criteria of diagnosis of MS as defined by the International', 'Paediatric Multiple Sclerosis Study Group criteria for paediatric MS (12) and the criteria of', 'MS based on McDonald criteria 2010 (18) (Appendix C).', 'Specific to the Russian Federation:', 'In the Russian Federation: Patients with RRMS aged >12 years to <18 years are eligible at', 'study entry (Appendix H).', \"I 02. Signed written informed consent/assent obtained from patient and patient's legal\", 'representative (parent or guardian) according to local regulations.', 'I 03.', 'Expanded Disability Status Scale (EDSS) score of 0.0 to 5.0 (inclusive) at screening', '(Appendix D).', 'I 04. At least 2 recorded MS attacks, and at least 1 MS attack (relapse) in the last year during', 'treatment with an IFNB or GA after having been on that therapy for at least 6 months, and', 'is currently still taking the same therapy.', 'I 05.', 'At least 1 of the following:', '-', '>1 new or enlarging T2 hyperintense lesion or gadolinium enhancing lesion while on', 'that same prior therapy (IFNB or GA), OR', '-', '2 or more relapses in the prior year, OR', '-', 'tried at least 2 MS DMTs.', '7.2', 'EXCLUSION CRITERIA', 'Patients who have met all the above inclusion criteria listed in Section 7.1 will be screened for the', 'following exclusion criteria which are sorted and numbered in the following 3 subsections:', 'NOTE: Prior to initiation of any alemtuzumab treatment course, contraindications should be', 'reviewed as pre-treatment verification of eligibility.', '7.2.1 Exclusion criteria related to study methodology', 'E 01. Any progressive or nonrelapsing forms of MS.', 'E 02. Conditions/situations such as:', '-', 'Impossibility to meet specific protocol requirements,', '-', 'Current participation in another interventional clinical study. If a patient has been', 'enrolled in a clinical trial and treated with a comparator agent that is an approved agent', 'Property of the Sanofi Group - strictly confidential', 'Page 41', 'VV-CLIN-02544065.0']\n\n###\n\n", "completion": "END"}